Neumora Therapeutics (NMRA)

• Market cap: $291M
• 1 day: 5.26%
• 5 days: 4.65%
• 1 month: -12.62%
• 3 months: -81.42%
• 6 months: -85.15%
• Year to date: -8.63%
• 1 year: -89.99%
• 5 years: -88.92%
• 10 years: -88.92%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Employees: 109

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

221% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 14

29% more funds holding

Funds holding: 103 [Q3] → 133 (+30) [Q4]

26% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 31

6.86% more ownership

Funds ownership: 42.89% [Q3] → 49.74% (+6.86%) [Q4]

5% more call options, than puts

Call options by funds: $64.8M | Put options by funds: $61.9M

6% less capital invested

Capital invested by funds: $906M [Q3] → $852M (-$54.5M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 289% upside
• Avg. target: $22 1,136% upside
• High target: $30 1,567% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 60 / 181 met price target	1,567% upside $30	Buy Reiterated	14 Feb 2025
B of A Securities Geoff Meacham 50% 1-year accuracy 15 / 30 met price target	289% upside $7	Buy Maintained	6 Jan 2025
Needham Ami Fadia 44% 1-year accuracy 73 / 167 met price target	1,178% upside $23	Buy Reiterated	2 Jan 2025
RBC Capital Brian Abrahams 16% 1-year accuracy 13 / 79 met price target	1,511% upside $29	Outperform Reiterated	22 Nov 2024